JP2015508763A5 - - Google Patents

Download PDF

Info

Publication number
JP2015508763A5
JP2015508763A5 JP2014556935A JP2014556935A JP2015508763A5 JP 2015508763 A5 JP2015508763 A5 JP 2015508763A5 JP 2014556935 A JP2014556935 A JP 2014556935A JP 2014556935 A JP2014556935 A JP 2014556935A JP 2015508763 A5 JP2015508763 A5 JP 2015508763A5
Authority
JP
Japan
Prior art keywords
amino acid
sequence
acid residues
seq
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014556935A
Other languages
English (en)
Other versions
JP2015508763A (ja
JP6400480B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/074093 external-priority patent/WO2013120554A1/en
Publication of JP2015508763A publication Critical patent/JP2015508763A/ja
Publication of JP2015508763A5 publication Critical patent/JP2015508763A5/ja
Application granted granted Critical
Publication of JP6400480B2 publication Critical patent/JP6400480B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (16)

  1. PGLYRP1に特異的に結合し、PGLYRP1に媒介されるTREM-1活性を低下させることができる抗体またはその断片。
  2. 配列番号37(II型1.0 PGLYRP1)および/または配列番号38(II型1.0 PGLYRP1)に特異的に結合することができる、請求項1に記載の抗体またはその断片。
  3. PGLYRP1との結合について抗体1F10、抗体1F36(mAb0182)、抗体1F95、抗体1F105(mAb0184)、抗体2F5および/または抗体2F7と競合することができる、請求項1または2に記載の抗体。
  4. 重鎖が、配列番号15のアミノ酸残基31〜35(SYWMN)に対応するCDRH1配列であって、前記アミノ酸残基の1つが異なるアミノ酸残基で置換されていてよい、CDRH1配列;および/または配列番号15のアミノ酸50〜66(MIHPSDSETRLNQKFKD)に対応するCDRH2配列であって、前記アミノ酸の1つ、2つまたは3つが異なるアミノ酸残基で置換されていてよい、CDRH2配列;および/または配列番号15のアミノ酸残基98〜108(DYSDYDGFAY)に対応するCDRH3配列であって、前記アミノ酸残基の1つ、2つまたは3つが異なるアミノ酸で置換されていてよい、CDRH3配列を含む、請求項1から3のいずれか一項に記載の抗体。
  5. 重鎖が、配列番号19のアミノ酸残基31〜35(DYNMY)に対応するCDRH1配列であって、前記アミノ酸残基の1つが異なるアミノ酸残基で置換されていてよい、CDRH1配列;および/または配列番号19のアミノ酸50〜66(YIDPYNGDTSYNQKFKG)に対応するCDRH2配列であって、前記アミノ酸の1つ、2つまたは3つが異なるアミノ酸残基で置換されていてよい、CDRH2配列;および/または配列番号19のアミノ酸残基99〜109(GDYGNPFYLDY)に対応するCDRH3配列であって、前記アミノ酸残基の1つ、2つまたは3つが異なるアミノ酸で置換されていてよい、CDRH3配列を含む、請求項1から3のいずれか一項に記載の抗体。
  6. 重鎖が、配列番号23のアミノ酸残基31〜35(DTYIH)に対応するCDRH1配列であって、前記アミノ酸残基の1つが異なるアミノ酸残基で置換されていてよい、CDRH1配列;および/または配列番号23のアミノ酸50〜66(RIDPANDDTKYDPNFQG)のCDRH2配列であって、前記アミノ酸の1つ、2つまたは3つが異なるアミノ酸残基で置換されていてよい、CDRH2配列;および/または配列番号23のアミノ酸残基99〜108(SDNSDSWFAY)のCDRH3配列であって、前記アミノ酸残基の1つ、2つまたは3つが異なるアミノ酸で置換されていてよい、CDRH3配列を含む、請求項1から3のいずれか一項に記載の抗体。
  7. 重鎖が、配列番号27のアミノ酸残基31〜35(DYNMH)に対応するCDRH1配列であって、前記アミノ酸残基の1つが異なるアミノ酸残基で置換されていてよい、CDRH1配列;および/または配列番号27のアミノ酸50〜66(YVDPYDGGTSSNQKFKG)に対応するCDRH2配列であって、前記アミノ酸の1つ、2つまたは3つが異なるアミノ酸残基で置換されていてよい、CDRH2配列;および/または配列番号27のアミノ酸残基99〜106(EVPYYFDY)に対応するCDRH3配列であって、前記アミノ酸残基の1つ、2つまたは3つが異なるアミノ酸で置換されていてよい、CDRH3配列を含む、請求項1から3のいずれか一項に記載の抗体。
  8. 重鎖が、配列番号31のアミノ酸残基31〜35(DYYMY)に対応するCDRH1配列であって、これらのアミノ酸残基の1つが異なるアミノ酸残基で置換されていてよい、CDRH1配列;および/または配列番号31のアミノ酸50〜66(AISDDSTYTYYPDSVKG)に対応するCDRH2配列であって、これらのアミノ酸の1つ、2つまたは3つが異なるアミノ酸残基で置換されていてよい、CDRH2配列;および/または配列番号31のアミノ酸残基99〜109(GGYGNLYAMDY)に対応するCDRH3配列であって、これらのアミノ酸残基の1つ、2つまたは3つが異なるアミノ酸で置換されていてよい、CDRH3配列を含む、請求項1から3のいずれか一項に記載の抗体。
  9. 重鎖が、配列番号35のアミノ酸残基31〜35(NYVMH)に対応するCDRH1配列であって、これらのアミノ酸残基の1つが異なるアミノ酸残基で置換されていてよい、CDRH1配列;および/または配列番号35のアミノ酸50〜66(WINPFNDGTNYNENFKN)に対応するCDRH2配列であって、これらのアミノ酸の1つ、2つまたは3つが異なるアミノ酸残基で置換されていてよい、CDRH2配列;および/または配列番号35のアミノ酸残基99〜109(SGFITTLIEDY)に対応するCDRH3配列であって、これらのアミノ酸残基の1つ、2つまたは3つが異なるアミノ酸で置換されていてよい、CDRH3配列を含む、請求項1から3のいずれか一項に記載の抗体。
  10. 軽鎖が、配列番号16のアミノ酸残基24〜34(RASQSISDYLH)に対応するCDRL1配列であって、前記アミノ酸残基の1つ、2つまたは3つが異なるアミノ酸で置換されていてよい、CDRL1配列;および/または配列番号16のアミノ酸残基51〜56(ASQSIS)に対応するCDRL2配列であって、前記アミノ酸残基の1つまたは2つが異なるアミノ酸で置換されていてよい、CDRL2配列;および/または配列番号16のアミノ酸残基89〜97(QNGHSFPLT)に対応するCDRL3配列であって、前記アミノ酸残基の1つまたは2つが異なるアミノ酸で置換されていてよい、CDRL3配列を含む、請求項4から9のいずれか一項に記載の抗体。
  11. 軽鎖が、配列番号20のアミノ酸残基24〜33(SVSSSVNYMY)に対応するCDRL1配列であって、前記アミノ酸残基の1つ、2つまたは3つが異なるアミノ酸で置換されていてよい、CDRL1配列;および/または配列番号20のアミノ酸残基49〜55(DTSKLPS)に対応するCDRL2配列であって、前記アミノ酸残基の1つまたは2つが異なるアミノ酸で置換されていてよい、CDRL2配列;および/または配列番号20のアミノ酸残基88〜96(QQWTSNPPT)に対応するCDRL3配列であって、前記アミノ酸残基の1つまたは2つが異なるアミノ酸で置換されていてよい、CDRL3配列を含む、請求項4から9のいずれか一項に記載の抗体。
  12. 軽鎖が、配列番号24のアミノ酸残基24〜33(SVSSSVNFMN)に対応するCDRL1配列であって、前記アミノ酸残基の1つ、2つまたは3つが異なるアミノ酸で置換されていてよい、CDRL1配列;および/または配列番号24のアミノ酸残基49〜55(DTSKLAP)に対応するCDRL2配列であって、前記アミノ酸残基の1つまたは2つが異なるアミノ酸で置換されていてよい、CDRL2配列;および/または配列番号24のアミノ酸残基88〜96(HQWSSYSLT)に対応するCDRL3配列であって、前記アミノ酸残基の1つまたは2つが異なるアミノ酸で置換されていてよい、CDRL3配列を含む、請求項4から9のいずれか一項に記載の抗体。
  13. 配列番号28のアミノ酸残基24〜33(VASSSVTYMY)に対応するCDRL1配列であって、前記アミノ酸残基の1つ、2つまたは3つが異なるアミノ酸で置換されていてよい、CDRL1配列;および/または配列番号28のアミノ酸残基49〜54(THPLAS)に対応するCDRL2配列であって、前記アミノ酸残基の1つまたは2つが異なるアミノ酸で置換されていてよい、CDRL2配列;および/または配列番号28のアミノ酸残基87〜95(PHWNTNPPT)に対応するCDRL3配列であって、前記アミノ酸残基の1つまたは2つが異なるアミノ酸で置換されていてよい、CDRL3配列をさらに含む、請求項4から9のいずれか一項に記載の抗体。
  14. 配列番号32のアミノ酸残基24〜35(TASSSVSSSYLH)に対応するCDRL1配列であって、これらのアミノ酸残基の1つ、2つまたは3つが異なるアミノ酸で置換されていてよい、CDRL1配列;および/または配列番号32のアミノ酸残基51〜57(STSNLAS)に対応するCDRL2配列であって、これらのアミノ酸残基の1つまたは2つが異なるアミノ酸で置換されていてよい、CDRL2配列;および/または配列番号32のアミノ酸残基90〜98(HQYHRSPFT)に対応するCDRL3配列であって、これらのアミノ酸残基の1つまたは2つが異なるアミノ酸で置換されていてよい、CDRL3配列をさらに含む、請求項4から9のいずれか一項に記載の抗体。
  15. 配列番号36のアミノ酸残基24〜34(KASESVGSFVS)に対応するCDRL1配列であって、これらのアミノ酸残基の1つ、2つまたは3つが異なるアミノ酸で置換されていてよい、CDRL1配列;および/または配列番号36のアミノ酸残基50〜56(GASNRYT)に対応するCDRL2配列であって、これらのアミノ酸残基の1つまたは2つが異なるアミノ酸で置換されていてよい、CDRL2配列;および/または配列番号36のアミノ酸残基89〜96(GQYYTHPT)に対応するCDRL3配列であって、これらのアミノ酸残基の1つまたは2つが異なるアミノ酸で置換されていてよい、CDRL3配列をさらに含む、請求項4から9のいずれか一項に記載の抗体。
  16. 炎症性疾患、心血管疾患、脳卒中、虚血再灌流傷害、肺炎、敗血症または癌の治療または予防のための、請求項1から15のいずれか一項に記載の抗体を含む医薬。
JP2014556935A 2012-02-15 2012-11-30 ペプチドグリカン認識タンパク質１に結合する抗体 Active JP6400480B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261598968P 2012-02-15 2012-02-15
US61/598,968 2012-02-15
EP12158974 2012-03-12
EP12158974.1 2012-03-12
US201261672799P 2012-07-18 2012-07-18
US61/672,799 2012-07-18
PCT/EP2012/074093 WO2013120554A1 (en) 2012-02-15 2012-11-30 Antibodies that bind peptidoglycan recognition protein 1

Publications (3)

Publication Number Publication Date
JP2015508763A JP2015508763A (ja) 2015-03-23
JP2015508763A5 true JP2015508763A5 (ja) 2016-01-21
JP6400480B2 JP6400480B2 (ja) 2018-10-03

Family

ID=48983555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014556935A Active JP6400480B2 (ja) 2012-02-15 2012-11-30 ペプチドグリカン認識タンパク質１に結合する抗体

Country Status (12)

Country Link
US (3) US9663568B2 (ja)
EP (2) EP2814842B1 (ja)
JP (1) JP6400480B2 (ja)
CN (2) CN104203977A (ja)
DK (1) DK2814842T3 (ja)
ES (1) ES2690786T3 (ja)
HR (1) HRP20181817T1 (ja)
LT (1) LT2814842T (ja)
PL (1) PL2814842T3 (ja)
RS (1) RS57827B1 (ja)
SI (1) SI2814842T1 (ja)
WO (1) WO2013120554A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2814842B1 (en) 2012-02-15 2018-08-22 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
CN103484468B (zh) * 2013-09-11 2015-04-08 华南农业大学 一种小菜蛾肽聚糖识别蛋白及其制备方法与应用
CN107106672B (zh) * 2015-01-12 2021-06-22 新加坡科技研究局 用于预防和治疗免疫介导性疾病的针对胞壁酰肽的单克隆抗体
WO2017083682A1 (en) * 2015-11-12 2017-05-18 The Board Of Trustees Of Leland Stanford Junior University Labeled probe and methods of use
CN107417773B (zh) * 2016-05-30 2020-09-08 国盛生化股份有限公司 黏合细胞壁之胜肽
WO2019032624A1 (en) * 2017-08-08 2019-02-14 Pionyr Immunotherapeutics, Inc. COMPOSITIONS AND METHODS FOR DEACTIVATING TREM1-EXPRESSING MESHLOID CELLS
US10836828B2 (en) 2019-02-06 2020-11-17 Pionyr Immunotherapeutics, Inc. Anti-TREM1 antibodies and related methods
CN109879956A (zh) * 2019-03-04 2019-06-14 哈尔滨工业大学 一种肿瘤免疫生物标志物及其应用
CN115611982B (zh) * 2021-07-14 2024-05-10 浙江大学 一种抗人MICA/Bα3区的单克隆抗体及其应用
CN115873109B (zh) * 2022-05-16 2024-02-09 江苏省中国科学院植物研究所 单克隆抗体及其在制备用于预防/治疗神经系统退行性疾病的生物制品中的应用

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE141646T1 (de) 1986-04-09 1996-09-15 Genzyme Corp Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2972257B2 (ja) 1990-01-24 1999-11-08 株式会社日立製作所 パケット交換機
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US4813316A (en) 1987-12-10 1989-03-21 Hobart Corporation Control system and method for a food product slicer
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL91501A (en) 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
JPH04501510A (ja) 1989-07-25 1992-03-19 セル　ジェネシス，インコーポレイティド 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同性組換え
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
CA2045175C (en) 1989-11-06 2003-03-18 Arthur I. Skoultchi Production of proteins using homologous recombination
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
MA22668A1 (fr) 1990-07-10 1993-07-01 Smithkline Beecham Corp Procede de preparation d'oxamides .
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DK0584279T3 (da) 1991-05-14 2001-06-11 Immune Response Corp Inc Målrettet aflevering af gener, som koder for immunogene proteiner
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2149774T3 (es) 1991-06-05 2000-11-16 Univ Connecticut Aportacion dirigida de genes que codifican proteinas secretoras.
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU3940293A (en) 1992-04-03 1993-11-08 Alexander T. YOUNG Gene therapy using targeted viral vectors
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
FR2694851B1 (fr) 1992-08-12 1994-12-23 Sgs Thomson Microelectronics Circuit de tirage vers un état déterminé d'une entrée de circuit intégré.
CA2141602A1 (en) 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU689758B2 (en) 1992-10-09 1998-04-09 Advanced Tissue Sciences, Inc. Liver reserve cells
CA2148252C (en) 1992-10-30 2007-06-12 Roger Brent Interaction trap system for isolating novel proteins
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
US6034217A (en) 1996-09-17 2000-03-07 Wako Pure Chemical Industries, Ltd. Peptidoglycan recognition proteins and their production
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US20030175858A1 (en) 1997-03-07 2003-09-18 Ruben Steven M. 186 human secreted proteins
US6420526B1 (en) 1997-03-07 2002-07-16 Human Genome Sciences, Inc. 186 human secreted proteins
WO1998039446A2 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 70 human secreted proteins
US6878687B1 (en) 1997-03-07 2005-04-12 Human Genome Sciences, Inc. Protein HMAAD57
WO1998039448A2 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
US20030049618A1 (en) 1997-03-07 2003-03-13 Ruben Steven M. 186 human secreted proteins
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
WO1998049198A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6172211B1 (en) 1997-07-11 2001-01-09 Boehringer Ingelheim International Gmbh Nucleic acid encoding tag7 polypeptide
WO1999018126A1 (fr) 1997-10-07 1999-04-15 Ono Pharmaceutical Co., Ltd. POLYPEPTIDE, ADNc LE CODANT ET LEUR UTILISATION
JP2002519030A (ja) 1998-06-26 2002-07-02 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトシグナルペプチド含有タンパク質
US20020172952A1 (en) 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6509448B2 (en) 1999-06-30 2003-01-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020197669A1 (en) 2000-12-13 2002-12-26 Bangur Chaitanya S. Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030170255A1 (en) 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1242443A4 (en) 1999-12-23 2005-06-22 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030134283A1 (en) 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
US7858094B2 (en) 2000-12-08 2010-12-28 Geneprint Corporation TREM-1 splice variant for use in modifying immune responses
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2342376C (en) 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
WO2003029401A2 (en) 2001-07-13 2003-04-10 Advanced Research And Technology Institute Peptidoglycan recognition protein encoding nucleic acids and methods of use thereof
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
EP2316485A1 (en) 2001-10-12 2011-05-04 Schering Corporation Use of bispecific antibodies to regulate immune responses
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
US20060263770A1 (en) 2002-03-22 2006-11-23 Marco Colonna Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
WO2004020591A2 (en) 2002-08-29 2004-03-11 Five Prime Therapeutics, Inc. Methods of use for novel human polypeptides encoded by polynucleotides
GB0305478D0 (en) 2003-03-10 2003-04-16 Bioxell Spa Diagnostic and prognostic compounds and method
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
DE10316701A1 (de) 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
WO2005048823A2 (en) 2003-11-17 2005-06-02 Janssen Pharmaceutica N.V. Modeling of systemic inflammatory response to infection
GB0401730D0 (en) 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
WO2005091944A2 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
PL1751184T3 (pl) 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
SI1789442T1 (sl) 2004-09-02 2010-01-29 Lilly Co Eli Proteinske mutante fibroblastnega rastnega faktorja 21
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
WO2006065582A2 (en) 2004-12-14 2006-06-22 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
SG172698A1 (en) 2006-06-12 2011-07-28 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
WO2008049113A2 (en) 2006-10-19 2008-04-24 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
JP2010516678A (ja) 2007-01-16 2010-05-20 ワイス エルエルシー Ｔｒｅｍ−１による炎症治療、検出およびモニタリング
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CN101821621A (zh) * 2007-07-23 2010-09-01 拜奥克塞尔有限公司 筛选、治疗和诊断
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
ES2646614T3 (es) 2007-08-03 2017-12-14 Eli Lilly And Company Uso de un compuesto de FGF 21 y un compuesto de GLP 1 para el tratamiento de la obesidad
CN101139599A (zh) * 2007-08-07 2008-03-12 西南大学 家蚕肽聚糖识别蛋白基因
KR20100058541A (ko) 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
EP2232271B1 (en) 2007-12-19 2019-09-11 Singulex, Inc. Scanning analyzer for single molecule detection and methods of use
US20090234202A1 (en) 2008-03-05 2009-09-17 Goix Philippe J Method and compositions for highly sensitive detection of molecules
US8697370B2 (en) 2008-05-23 2014-04-15 Pronota N.V. Biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
BRPI0917130A2 (pt) 2008-08-25 2015-12-01 Centocor Ortho Biotech Inc biomarcadores para tratamento anti-tnf de colite ulcerativa e transtornos relacionados
NZ592009A (en) 2008-10-10 2012-11-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CN101619102A (zh) * 2008-12-16 2010-01-06 中国科学院海洋研究所 一种具杀菌活性的栉孔扇贝肽聚糖识别蛋白的制备及应用
US9480753B2 (en) 2009-01-23 2016-11-01 Novo Nordisk A/S FGF21 derivatives with albumin binder A-B-C-D-E- and their use
WO2010132370A2 (en) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Soluble tlt-1 for the treatment and diagnosis of sepsis
US8911960B2 (en) 2009-06-01 2014-12-16 Case Western Reserve University Method for identifying idiopathic pneumonia progression by measuring the level of mannose-binding protein C
WO2010142665A1 (en) 2009-06-11 2010-12-16 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
BRPI1015234A2 (pt) 2009-06-22 2018-02-20 Medimmune Llc regiões fc projetadas para conjugação sítio específica.
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011047097A2 (en) 2009-10-13 2011-04-21 Sigalov Alexander B Inhibition of trem receptor signaling with peptide variants
KR101251023B1 (ko) 2009-11-05 2013-04-03 주식회사유한양행 신규한 단일클론항체를 포함하는 박테리아 감염 검출용 키트
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
SG185107A1 (en) 2010-04-30 2012-12-28 Alexion Pharma Inc Antibodies having reduced immunogenicity in a human
EP2638066A4 (en) 2010-11-09 2015-06-03 Medimmune Llc ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US20120213781A1 (en) 2011-02-11 2012-08-23 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
EP2814842B1 (en) 2012-02-15 2018-08-22 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1

Similar Documents

Publication Publication Date Title
JP2015508763A5 (ja)
JP2015508762A5 (ja)
IL261585A (en) Antigen-binding human proteins that bind beta-klotho, fgf receptors and their complexes
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
RU2747735C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
AR082916A1 (es) Moleculas de union a 4-1bb
AR081556A1 (es) Proteinas de union al antigeno humanizadas
RU2020129387A (ru) Антитела к pd-1 собак
JP2020500538A5 (ja)
HRP20211343T1 (hr) Protutijela protiv dkk-1
JP2012505912A5 (ja)
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
PE20142242A1 (es) Anticuerpos humanos anti-cd27, metodos, y usos
HRP20171472T1 (hr) Optimizirana monoklonska protutijela protiv inhibitora puta tkivnog faktora (tfpi)
HRP20161298T1 (hr) Novi antagonisti protutijela i njihovi fab fragmenti protiv gpvi i njihova uporaba
NZ610153A (en) Novel anti-dr5 antibody
ES2571129T3 (es) Anticuerpos anti-CTLA4 humanizados
NZ630433A (en) Antibodies and uses thereof to detect folate receptor 1
NZ602905A (en) Fgf-r4 receptor-specific antagonists
JP2010536384A5 (ja)
JP2012502649A5 (ja)
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
JP2014205674A5 (ja)
JP2011518125A5 (ja)
PE20170687A1 (es) Proteinas de enlace a cd127